Effectiveness and Safety of Method of Maxilla Alveolar Process Reconstruction Using Synthetic Tricalcium Phosphate and Autologous MMSCs
Effectiveness and Safety of Method of Maxilla Alveolar Process Reconstruction Using Tissue Engineered Construction Based on a Synthetic Tricalcium Phosphate and Autologous Multipotent Mesenchymal Stromal Cells Obtained From Oral Mucosa
Sponsor: Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
This PHASE1/PHASE2 trial investigates Alveolar Bone Atrophy and Alveolar Bone Loss and is currently ongoing. Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
-
Dec 2018 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
Status: Enrolling By Invitation → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Dec 2018 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Jan 2017 — Oct 2017 [monthly]
Enrolling By Invitation PHASE1_PHASE2
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
For direct contact, visit the study record on ClinicalTrials.gov .